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This study was designed to test the efficacy of nitroglycerin 
and diltiazem in inhibiting in vivo platelet aggregation and 
reducing platelet-mediated vasoconstriction in a canine 
model of coronary artery stenosis and endothelial injury. 
Coronary artery diameter was measured in vivo by means of 
ultrasonic crystals sutured on the left anterior descending 
coronary artery (LAD) immediately distal to an external 
constrictor (LADl), 1 cm below (LADZ), and on the left 
circumflex coronary artery. Coronary diameter was contin- 
uously measured before, during cyclic flow variations (pro- 
gressive declines in blood flow followed by sudden restora- 
tions of flow due to recurrent intracoronary platelet 
aggregation), during cyclic flow variations and intravenous 
infusion of nitroglycerin (5 /&kg per min) or diltiazem (15 
dkg per mitt), and after cyclic flow variations were abol- 
ished by administration of LY53857, a serotonin receptor 
antagonist (n = 7), or SQ29548, a thromboxane A2 receptor 
antagonist (n = 7). 
During control cyclic flow variations, at the nadir of 
coronary Row (6% to 11% of the nonstenosed values), LAD1 
cross-sectional area decreased by 43 f 8% and 44 f 3% in 
the two groups of dogs subsequently treated with LY53857 
and SQ29548, respectively. Neither nitroglycerin nor dilti- 
azem caused changes in cyclic flow variation frequency or 
severity. Furthermore, neither drug significantly reduced 
the vasoconstriction associated with cyclic flow variations, 
whereas they significantly increased circumflex artery cross- 
sectional area. In contrast, LY53857 and SQ29548 were very 
effective in abolishing cyclic flow variations and the coronary 
vasoconstriction related to them. Five additional dogs re- 
ceived an intracoronary infusion of nitroglycerin (21 f 5 
&kg per min) and later diltiazem (15 &kg per min). 
Again, neither drug decreased the coronary vasoconstriction 
associated with cyclic flow variations. A modest antiplatelet 
effect was observed during intracoronary infusion of nitro- 
glycerin as cyclic flow variation frequency decreased from 
7.7 2 0.4 to 5.6 f 0.5 cycles/30 min during control cyclic 
flow variations (p < 0.05). 
It is concluded that nitroglycerin and diltiazem are 
relatively ineffective in inhibiting marked in vivo platelet 
aggregation and platelet-mediated vasoconstriction in this 
experimental model. This study provides further evidence 
that thromboxane A, and serotonin are mediators of plate- 
let-mediated vasoconstriction in this experimental model. 
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01990 by the American College of Cardiology 
The factors responsible for the conversion from chronic to 
acute coronary artery disease, including the development of 
unstable angina and acute myocardial infarction, remain 
incompletely defined. However, several studies (l-6) indi- 
cate that in most patients unstable angina is the consequence 
of platelet aggregation and in situ thrombosis at sites of 
coronary artery narrowing and endothelial injury. Hirsh et 
al. (6) described the occurrence of increases in thromboxane 
A, concentration in the coronary sinus of patients with 
unstable angina; their findings were subsequently confirmed 
by others (7,B). These data demonstrate a temporal relation 
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between the development of unstable angina and increases in 
transcardiac thromboxane concentration in patients, consis- 
tent with the hypothesis that intracoronary platelet activa- 
tion is an important factor in the pathogenesis of unstable 
angina. In addition, mediators with vasoconstricting effects, 
such as thromboxane A, and serotonin, released by acti- 
vated platelets may contribute to the pathogenesis of unsta- 
ble angina through a further reduction of blood flow. 
Nitroglycerin and diltiazem have been shown to relax 
vascular smooth muscle and dilate coronary and systemic 
arterial beds (9-13). Both drugs are widely employed for the 
prevention and relief of myocardial ischemia, and they are 
currently used in the treatment of unstable angina. In large 
concentration, nitroglycerin also inhibits platelet function in 
vitro (14) and has been reported (15) to prolong the bleeding 
time in humans. Similarly, diltiazem inhibits platelet activa- 
tion both in vitro and in vivo (16,17). In addition, Lam et al. 
(18) recently reported that intravenous nitroglycerin reduces 
the extent of platelet deposition and the associated vasocon- 
striction in porcine carotid arteries subjected to experimen- 
tal angioplasty. 
The goal of the present study was to assess whether 
nitroglycerin and diltiazem inhibit platelet aggregation in 
vivo and reduce activated platelet-mediated coronary artery 
vasoconstriction. We used the canine model of coronary 
artery stenosis and endothelial injury initially described by 
Felts et al. (19), in which repeated episodes of spontaneous 
decreases in coronary blood flow are followed by sudden 
restorations of flow (cyclic flow variations). Previous studies 
(19-22) have shown that the cyclic flow variations result 
from alternating platelet aggregation and dislodgment at the 
stenotic site. In studies with this in vivo model of intracor- 
onary platelet aggregation, we suggested previously (20,22- 
24) that serotonin and thromboxane A, released from acti- 
vated platelets are important mediators of cyclic flow 
variations. Recently, we have also shown (25). in the same 
experimental preparation, that intracoronary platelet activa- 
tion associated with cyclic flow variations causes a marked, 
focal constriction of the coronary arterial segments where 
platelets accumulate maximally. Thromboxane A, and sero- 
tonin released by activated platelets appear to play a major 
role in mediating coronary vasoconstriction in this model 
because the administration of a thromboxane A,/prostaglan- 
din H, or a serotonin S, receptor antagonist abolishes the 
coronary vasoconstriction (2.5). 
The present study provides evidence that nitroglycerin 
and diltiazem are relatively ineffective in inhibiting cyclic 
flow variations and decreasing coronary vasoconstriction 
caused by activated platelets in this experimental model. 
Methods 
Surgical preparation. Experiments in this study were Protocol A: intravenous infusion. After cyclic flow varia- 
performed in compliance with the position of the American tions were observed for 30 min, 14 dogs received an intra- 
Heart Association on research animal use. Twenty mongrel 
dogs (30 to 45 kg) of either gender were anesthetized with 
intravenous sodium pentobarbital (30 mg/kg body weight) 
and ventilated with room air by a Harvard respirator. 
Heating pads were placed under the animal to maintain 
rectal temperature. A left thoracotomy was performed at the 
fifth intercostal space and the heart was suspended in a 
pericardial cradle. A segment of the left anterior descending 
coronary artery was gently dissected from the surrounding 
tissue and a pulsed Doppler flow probe was placed around it, 
proximal to where a constrictor would subsequently be 
positioned. A 1 cm segment immediately distal to the flow 
probe was then endothelially injured by gently squeezing the 
artery between a pair of rubber-covered forceps. One pair of 
miniature 7 MHz ultrasonic crystals (2 X 1 mm, 12 mg. 
Triton Technology) attached to a Dacron backing was su- 
tured to the adventitia of opposing sides of the left anterior 
descending coronary artery immediately distal to the steno- 
sis (LADl) with a 6-O silk thread (Ethicon). A second pair of 
ultrasonic crystals was sutured more distally (1 to 1.5 cm 
beyond the first one) on this artery (LAD2). taking care not 
to damage the endothelium. A third pair of crystals was 
implanted on the left circumflex coronary artery. Finally, a 
small heparin-filled polyethylene catheter was positioned in 
the distal end of the diagonal branch of the left anterior 
descending artery below the site of constriction, enabling the 
pressure gradient across the stenosis to be measured (Fig. 1). 
In six dogs, a second intracoronary catheter was positioned 
in another small diagonal branch proximal to the constrictor 
to infuse drugs directly into the left anterior descending 
artery. 
Experimental protocol. After the surgical procedures 
were completed, the dogs were allowed to stabilize for 230 
min. Control measurements of heart rate, systemic and 
coronary artery pressure and mean and phasic coronary 
blood flow velocity as well as external diameter of LADl. 
LAD2 and the circumflex artery were recorded continuously 
on a Hewlett-Packard (model 7758) eight channel recorder. 
A plastic 2 to 3 mm long cylindrical constrictor was placed 
around the left anterior descending artery between the 
Doppler flow probe and the first pair of crystals (Fig. I) as 
previously described (20,22). This usually results in intracor- 
onary platelet activation and occurrence of cyclic flow 
variations. Once cyclic flow variations occurred, they were 
observed for 30 min. During this period, cyclic flow variation 
frequency, phasic and mean coronary blood flow velocity, 
heart rate and systemic and distal coronary blood pressures, 
as well as LAD1 , LAD2 and left circumflex artery diastolic 
diameters were recorded. Coronary artery flow velocity and 
coronary diameters were compared with values for the same 
variables before constricting the left anterior descending 
artery. 
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Figure 1. Schematic representation of the instrumentation used in 
this study. Endothelium was removed and a plastic constrictor was 
placed around the left anterior descending coronary artery (LAD). A 
Doppler flow probe was positioned just proximally to the constric- 
tor. A pair of ultrasonic crystals was sutured on the left anterior 
descending artery immediately distal to the constrictor (LADI), 
where we have previously shown platelet deposition to be maximal. 
A second pair of crystals was sutured 1 to 1.5 cm below the first one 
(LAD2), where little or no platelet deposition occurs. Finally, a third 
pair of ultrasonic crystals was sutured on the left circumflex 
coronary artery (CX) and served as a control. See text for details. 
Ao = aorta; PA = pulmonary artery; RV = right ventricle. 
venous infusion of nitroglycerin (5 &kg per min, Nitrostat, 
Parke-Davis, diluted in 50 ml of saline solution) for 30 min. 
After discontinuing nitroglycerin and when hemodynamics 
returned to prenitroglycerin values, an intravenous infusion 
of diltiazem (15 CLg/kg per min, Cardizem, Marion, dissolved 
in 50 ml of saline solution) for 30 min was started. After the 
infusion of diltiazem was discontinued, these animals re- 
ceived an intravenous bolus of either LY53857, a selective 
serotonin S, receptor antagonist (Lilly) (n = 7) (26,27), or 
SQ29548, a thromboxane A,/prostaglandin H, receptor an- 
tagonist (28) (Squibb) (n = 7) to abolish cyclic flow varia- 
tions. LY53857 was dissolved in 20 ml of saline solution, 
whereas SQ29548 was dissolved in 1 ml of ethanol and 
diluted in 20 ml of saline solution. The dose of SQ29548 and 
LY53857 required to abolish cyclic flow variations averaged 
0.25 t. 0.11 and 0.13 r 0.05 mg/kg, respectively. 
Protocol B: intracoronary infusion. To increase the intra- 
coronary concentration of nitroglycerin and diltiazem with- 
out causing profound hemodynamic changes, these drugs 
were infused directly into the left anterior descending artery 
through a small catheter placed proximally to the constric- 
tor. One dog in this group did not develop cyclic flow 
variations after placement of the constrictor around the 
vessel. The remaining five dogs in this group were subjected 
to the procedures described in Protocol A except that 
nitroglycerin and diltiazem were infused through the intra- 
coronary route. Nitroglycerin infusion was started at a dose 
of 5 pg/kg per min and progressively increased to produce a 
reduction in mean arterial pressure similar to that obtained in 
the intravenous infusion groups. This hemodynamic re- 
sponse required a dose of 21 f 5 pg/kg per min intracoronary 
nitroglycerin with a flow rate never exceeding 2 mllmin. 
Intracoronary infusion of diltiazem was maintained constant 
at the dose of 15 pgikg per min for 30 min because we 
noticed a high incidence of heart block with higher doses 
(29). At the end of the diltiazem infusion, dogs in this group 
received an intravenous bolus of SQ29548 as described for 
the previous two groups of animals. The dose of SQ29548 
required to abolish cyclic flow variations in this group of 
animals averaged 0.27 + 0.14 mg/kg. 
Measurement of coronary diameter in vivo. Coronary 
artery diameter was measured continuously with an ultra- 
sonic dimension gauge (Triton Technology, model 120.2). 
The instrument generates a voltage linearly proportional to 
the transit time of acoustic impulses traveling at the sonic 
velocity of 1.5 x lo6 mm/s between the 7 MHz piezoelectric 
crystals, thus giving a record of instantaneous external 
coronary artery diameter. The transit time technique has 
been applied to measurement of coronary artery dimensions 
by Vatner et al. (30) and it has been demonstrated to be 
accurate and reliable (30-33). 
As external diameter was measured continuously, the 
internal diameter and the cross-sectional area of the vessels 
at the site of crystal implantation were calculated as previ- 
ously described (29,30), knowing the length of the arterial 
segment measured in vivo and its weight measured postmor- 
tem. 
Changes in left anterior descending and circumflex artery 
internal diameter and cross-sectional area were related to 
values obtained before cyclic flow variations (control) but 
with the constrictor in place on the left anterior descending 
artery. In this model, we have previously demonstrated that 
a marked decrease in distal left anterior descending artery 
distending pressure occurs at the nadir of coronary blood 
flow during cyclic flow variations. To distinguish the passive 
decrease in left anterior descending artery diameter conse- 
quent to a reduction of coronary distending pressure from 
actual vasoconstriction due to activation of arterial smooth 
muscle cells, we compared coronary artery dimensions 
obtained during cyclic flow variations to those recorded 
during a 10 s mechanical occlusion of the left anterior 
descending artery produced by a suture snare placed proxi- 
mally to the Doppler flow probe. Measurements of coronary 
diameter during mechanical occlusion were made early in 
the experiments before the onset of cyclic flow variations but 
with the constrictor in place. 
Statistical analysis. Results are expressed as mean values 
f SEM. Comparisons among means were made with use of 
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a two-way analysis of variance. For comparisons of hemo- 
dynamics and coronary artery dimensions among groups, a 
two-way analysis of variance with a design for repeated 
measures was used. 
Results 
Placement of the left anterior descending artery constric- 
tor reduced mean coronary blood velocity to 74 t 5% of 
control and eliminated the hyperemic response to a total 
brief coronary occlusion. Among 20 dogs, cyclic flow vari- 
ations were successfully produced in 19. In the intravenous 
infusion group, LY.53857 and SQ29548 each abolished cyclic 
flow variations in six of seven dogs. In the intracoronary 
infusion group, SQ29548 abolished cyclic flow variations in 
five of five dogs. 
Protocol A: Intravenous Infusion 
Effects of nitroglycerin and diltiazem on cyclic flow varia- 
tions and hemodynamics. In dogs receiving nitroglycerin and 
diltiazem intravenously, neither drug changed cyclic flow 
variation severity (defined as the lowest coronary flow 
velocity recordable, Table 1) and frequency (Fig. 2A). Heart 
rates and arterial pressures for the two groups of dogs 
subsequently treated with LY53857 and SQ29548 included in 
the intravenous infusion protocol are summarized in Table I. 
Both nitroglycerin and diltiazem decreased mean arterial 
pressure by an average of 20% in both groups. Administra- 
tion of diltiazem was associated with a significant reduction 
in heart rate in both groups, whereas nitroglycerin adminis- 
tration did not cause any significant change in this variable. 
Distal coronary artery pressures measured before the place- 
ment of the constrictors were consistently lower than aortic 
pressures in both groups. This difference can probably be 
attributed to the small size of the catheters used to cannulate 
the small side branch of the left anterior descending artery. 
Coronary artery dimension changes. The brief mechani- 
cal coronary artery occlusion caused a decrease in LAD1 
cross-sectional area of 18 t 3% and 20 * 4% of the control 
values in dogs subsequently treated with LY53857 and 
SQ29548. respectively. Similarly, LAD2 cross-sectional ar- 
eas decreased by 19 + 6% and 19 f 5%, respectively, as 
compared with control values in the same groups of animals. 
In contrast, during cyclic flow variations, LAD1 cross- 
sectional areas, at the nadir of flow, decreased by 43 k 8% 
and 44 k 3% from control values in dogs subsequently 
treated with LY53857 and SQ29548, respectively. These 
values represent an average of at least three cycles and were 
both significantly different from those obtained during the 
brief mechanical occlusion (Fig. 3). LAD2 cross-sectional 
area at the nadir of coronary flow during cyclic flow varia- 
tions was not different from the values recorded during the 
brief mechanical occlusion in both groups (Fig. 3). Nitro- 
Table 1. Hemodynamic Effects of Intravenous Infusions of 
Nitroglycerin and Diltiazem in Dogs With Cyclic Flow Variations 
HR MAP DCMP MNF 
(beats/mm) (mm Hg) (mm Hg) (% Control) 
Group I (LY53857) 
Control 128 + 9 112 -+ 6 98 r 8 100 
Constricted 130 2 9 110 ? 6 68 + 12* 74 ? 6* 
CAQ 129 + 6 113 ? 5 19 2 6* 4 + 2* 
CFVs Peak 127 2 6 113 2 3 66 2 14 88 ? 15 
Nadir 128 ? 6 110 t 3 28 +- 6* 6 + 3* 
Nitroglycerin Peak 133 ? 7 92 t 4* 60 -t 12* 91 ? 12 
Nadir 131 + 7 89 t 4* 30 i- 5* 10 + 4* 
Diltiazem Peak 115 t II* 91 + 3* 64 t 8* 892 14 
Nadir 113 t IO* 90 If- 4* 30 -+ 6* 9 t 4* 
Post LY53857 115 ? II* 94 t 3* 79 t- 7% 93 2 12 
Group II (SQ29548) 
Control 128 2 8 106 i 5 92 i 7 100 
Constricted 124 2 9 106 + 6 64 ? 14* 77 + 8 
CAQ 123 2 9 105 t 7 ?I i- 7* 5 + 3* 
CFVs Peak 126 + 8 103 -r 3 68 + I?* 84 + 12* 
Nadir 131 t 9 106 + 4 26 + 8* 7 + 4* 
Nitroglycerin Peak 136 t 8 83 + 5* 68 + 12* 9 2 7* 
Nadir 132 5 7 81 ? 4* 29 + .(* 87 of- 14 
Diltiazem Peak 115 t 16* 84 -’ 6* 65 ? 13* 11 *5* 
Nadir 112 2 5* 83 + 3* 27 +- 7* 89 + IS* 
Post SQ29548 112 t 4* 91 + 5* 77 + 9* 902 14 
*Significantly different from original control value (p < 0.05). Nadir is 
defined as the lowest flow velocity recorded just before flow restoration, 
Values are expressed as mean values It SEM. CA0 = coronary artery 
occlusion (obtained by a surgical suture snare); CFVs = cyclic flow varia- 
tions: DCMP = distal coronary mean pressure: HR = heart rate: MAP = 
mean arterial pressure: MNF = mean coronary blood flow velocity. See text 
for details. 
glycerin tended to reduce LAD1 vasoconstriction during 
cyclic flow variations as LAD1 cross-sectional area de- 
creased by 37 k 8% and 40 2 3% in animals subsequently 
treated with LY53857 and SQ29548, respectively, as com- 
pared with 43 + 8% and 44 2 3%, respectively, during the 
control cyclic flow variations, but these differences were not 
statistically significant. LAD1 cross-sectional area during 
diltiazem infusion decreased by 35 2 7% and 39 k 2%, 
respectively, in the two groups, values not different from 
those recorded during the first 30 min of cyclic flow varia- 
tions. Nitroglycerin and diltiazem did not change LAD2 
cross-sectional area during cyclic flow variations. 
Finally, both LY53857 and SQ29548 were effective in 
abolishing cyclic coronary flow variations and in preventing 
coronary vasoconstriction. However, they affected left an- 
terior descending artery dimensions differently: LAD I 
cross-sectional area increased by 12 2 3% of the control 
value in the SQ29548-treated group as cyclic flow variations 
were abolished; whereas in the LY53857-treated dogs, it 
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Figure 2. Top, Cyclic flow variation (CFV) frequency (cycles/30 
min) in dogs during initial measurements and after intravenous 
infusion of nitroglycerin (5 &kg per min) or diltiazem (15 &kg per 
min), and after the administration of either SQ29548 (closed bars, 
n = 7) or LY53857 (open bars, n = 7). Nitroglycerin and diltiazem 
did not change cyclic flow variation frequencies, whereas both 
SQ29548 and LY53857 abolished them in six of the seven dogs. *p < 
0.001. Bottom, Cyclic flow variation frequency in dogs receiving 
intracoronary infusion of nitroglycerin (21 ? 5 CLg/kg per min) or 
diltiazem (15 pglkg per min). Nitroglycerin caused a significant 
decrease in cyclic flow variation frequency, whereas diltiazem did 
not change this variable. SQ29548 abolished cyclic flow variations in 
five of the five dogs in this group. *p < 0.001. 
returned to control dimensions as the cyclic flow variations 
were abolished (Fig. 3). Circumflex artery cross-sectional 
area showed a small but significant increase during infusion 
of nitroglycerin and diltiazem in both groups. This effect 
persisted 30 min after discontinuation of the infusion of 
diltiazem (Fig. 3). 
Protocol B: Zntracoronary Znfusion 
Effects of nitroglycerin and diltiazem on cyclic flow varia- 
tions and hemodynamic changes. Intracoronary infusion of 
nitroglycerin at the dose of 21 ? 5 pg/kg per min was 
associated with a small but significant decrease in cyclic flow 
variation frequency from 7.7 2 0.4 to 5.6 +- 0.5 cycles/30 min 
(p < 0.05) (Fig. 2B). Initial cyclic flow variation frequency 
returned to control values promptly after nitroglycerin infu- 
sion was stopped. Diltiazem ha4 no effect on cyclic flow 
variation frequency, whereas SQ29548 completely abolished 
cyclic flow variations in this group of dogs (Fig. 2B). 
Table 2 summarizes heart rate and systemic arterial 
-804 I 
CAD NADIR PEAK NADIR PEM NADIR PEM PDST LY 
20 1 ??
-50 II 
CM NADIR PEAK NFglR Pv NhflR PEfM PDSTSD 
RWb-~n Dllttaznfq 
cl% 
Figure 3. Changes in coronary diastolic cross-sectional areas in dogs 
with cyclic flow variations (CFVs) receiving intravenous nitroglyc- 
erin (5 pglkg per min) or diltiazem (15 lLgikg per min). A marked 
reduction in cross-sectional areas was observed at the LAD1 
(proximal) site (open circles). This value was significantly different 
from that obtained during a brief mechanical occlusion (CAO) of the 
left anterior descending artery. However, at a more distal site 
(LAD2, filled circles), no significant coronary vasoconstriction was 
observed. Note that nitroglycerin and diltiazem, despite a significant 
vasodilating effect on the circumflex coronary artery (CX, filled 
squares), did not reduce the marked LAD1 vasoconstriction associ- 
ated with cyclic flow variations as compared with control values. 
Top, Dogs subsequently treated with LY53857. Bottom, Dogs sub- 
sequently treated with SQ29548. *p < 0.05 versus control; **p < 
0.05 versus CAO. 
pressure values for dogs included in the intracoronary infu- 
sion protocol. Again, nitroglycerin caused a significant re- 
duction in mean arterial pressure of about 25%. However, to 
achieve similar hemodynamic effects to those observed in 
the intravenous infusion groups, the dose had to be in- 
creased up to 21 2 5 &kg per min. Diltiazem, at the same 
dose used intravenously, caused hemodynamic changes in 
heart rate and arterial pressure comparable to those ob- 
served in the intravenous infusion groups. 
Coronary artery dimension changes. The brief mechani- 
cal left anterior descending occlusion caused a similar de- 
crease in LAD1 and LAD2 cross-sectional areas of 16 2 3% 
JACC Vol. 15, No. 3 GOLINO ET AL. 123 
March I. 1990:718-26 PLATELET-INDUCED VASOCONSTRICTION 
Table 2. Hemodynamic Effects of Intracoronary Infusions 
of Nitroglycerin and Diltiazem in Five Dogs With Cyclic 
Flow Variations 
HR 
(beatsimin) 
MAP DCMP MNF 
(mm Hg) (mm Hg) (% Control) 
Control 121 t IO 107 ? 8 94 + 8 loo 
Constricted 127 t IO 110 + 7 68 t 9* 7s + 5* 
CA0 126 + 11 108 ? 7 I5 + 6* 3 t 2* 
CFVs Peak 124 ? 9 110 I6 66 + 8 88 2 II 
Nadir 126 2 7 110 + 6 28 + 6* 8 2 4* 
Nitroglycerin Peak 125 It 8 85 + 6* 60 + 10* 87 + 12 
Nadir 124 ? 7 86 + 6* 30 ? 5* 9 2 4* 
Diltiazem Peak 113 + II* 92 of: 5* 62 ? 8* 862 I2 
Nadir 113 t IO* 91 t 6* 30 2 7* 9 ? 4* 
Post SO29548 115 + II* 94 t 6* 75 ? 8* 902 I2 
*Significantly different from original control value p < 0.05. Nadir is 
defined as the lowest flow velocity recorded just before flow restoration. 
Values are expressed as mean values + SEM. Abbreviations as in Table I. 
and 14 f 4% of the control values, respectively (Fig. 4). 
During cyclic flow variations, at the nadir of flow, LAD1 
cross-sectional area decreased by 43 t 3% (p < 0.05 versus 
coronary occlusion), whereas LAD2 cross-sectional area 
decreased by only 18 -t 3% (p = NS versus coronary 
occlusion, Fig. 4). Thus also in this group, cyclic flow 
variations were associated with a marked vasoconstriction 
of the left anterior descending artery segment adjacent to the 
constrictor. Infusion of nitroglycerin directly into the left 
anterior descending artery proximally to the constrictor at a 
Figure 4. Changes in coronary artery diastolic cross-sectional areas 
in dogs with cyclic flow variations (CFVs) receiving intracoronary 
infusions of nitroglycerin (21 t 5 pguglkg per min) or diltiazem (15 
pg/kg per min). Again, nitroglycerin and diltiazem, despite a signif- 
icant vasodilating effect on the left circumflex coronary artery (CX, 
filled squares), did not reduce the marked LAD1 (open circles) 
vasoconstriction associated with cyclic flow variations compared 
with control cyclic flow variations. *p < 0.05 versus control; **p < 
0.05 versus CAO. Other abbreviations and symbols as in Figure 3. 
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dose of 21 ? 5 M/kg per min slightly reduced this vasocon- 
striction to 38 t 4% of the control values, but this difference 
did not reach statistical significance (Fig. 4). Intracoronary 
infusion of diltiazem did not cause any change in LAD1 and 
LAD2 cross-sectional areas with respect to the values re- 
corded during the initial cyclic flow variations. Circumflex 
artery cross-sectional areas increased significantly during 
intracoronary infusion of nitroglycerin and diltiazem. Again, 
this effect persisted 30 min after the infusion of diltiazem was 
stopped (Fig. 4). 
Discussion 
Nitroglycerin, diltiazem and platelet function. The vascu- 
lar effects of nitroglycerin (and other nitrovasodilators) are 
believed to be mediated through a direct activation of soluble 
guanylate cyclase in smooth muscle (33-35); therefore, they 
act independently of an intact endothelium. Because of its 
potent vasodilating effects, nitroglycerin has been widely 
used for the prevention and relief of myocardial ischemia, as 
well as for the treatment of unstable angina. Despite the 
widespread use of nitroglycerin, the mechanisms underlying 
its remarkable efficacy in treating acute ischemic heart 
disease syndromes, such as unstable angina, where intracor- 
onary platelet activation is believed to play a major patho- 
physiologic role (l-5), are not completely understood. Pre- 
vious studies (14,15) have shown that nitroglycerin can 
inhibit platelet function both in vitro and in vivo, suggesting 
that this mechanism might help explain the efficacy of this 
drug in patients with unstable angina. Similarly, diltiazem, a 
calcium channel blocker, has been shown to possess vasodi- 
lating and antiplatelet properties (12,13,16,17), which have 
been suggested to be the result of a reduction in the increase 
in intracellular calcium concentration in response to various 
agonists (36). 
These observations, together with the recent demonstra- 
tion (18) that nitroglycerin can reduce the extent of carotid 
artery platelet deposition and the vasoconstriction related to 
it after experimental angioplasty, prompted us to test the 
efficacy of nitroglycerin and diltiazem in inhibiting intracor- 
onary platelet activation and reducing activated platelet- 
dependent coronary vasoconstriction in an experimental 
model characterized by a severe coronary artery stenosis 
and endothelial injury. 
Platelet activation and vasoconstriction. In this experi- 
mental preparation, endothelial damage associated with a 
severe coronary artery stenosis usually results in a cyclic 
pattern of reductions and restorations of coronary flow that 
is caused by recurrent episodes of platelet aggregation and 
subsequent dislodgment of the thrombus (19-24). It has been 
-606 demonstrated (37-40) that, when the platelets aggregate, 
CM NADIR PEAK NADIR PEAK NADIR PEW POSTS4 they release several substances, including serotonin and 
I N&$&l” Dtlthzem thromboxane A,, that are known to cause vasoconstriction 
CWS and to further promote aggregation. In a recent study from 
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Table 3. Effects of Intravenous and Intracoronary Infusion of Nitroglycerin and Diltiazem on Diastolic Cross-Sectional Area (mm*) in 12 
Dogs With Cyclic Flow Variations 
Cyclic Flow Variations 
Intravenous 
Infusion (n = 7) 
Group I (SQ29548) 
LAD1 
LAD2 
LCX 
Group II (LY53857) 
LAD1 
LAD2 
LCX 
Intracoronary 
Infusion (n = 5) 
LAD1 
LAD2 
LCX 
Control 
5.9 + 1.4 
5.0 * 1.7 
7.4 ? 2.1 
6.1 2 1.8 
5.3 * 2.0 
7.6 ? 2.5 
6.4 2 2.2 
5.7 2 2.4 
8.0 2 2.3 
CA0 
4.7 + 1.7 
4.2 2 1.9 
7.4 * 2.0 
5.0 + 1.9 
4.3 ? 2.1 
7.6 ? 2.4 
5.4 + 2.3 
4.9 + 2.5 
8.0 ? 2.3 
Nadir 
3.3 ? 1.6 
4.0 2 1.8 
7.4 + 2.1 
3.5 + 2.0 
3.9 + 1.9 
7.6 + 2.5 
4.0 + 2.4 
4.7 i 2.5 
8.0 f 2.4 
Peak 
5.9 t 1.5 
4.9 2 1.6 
7.4 2 2.2 
6.0 t 1.9 
5.2 t 1.9 
7.5 + 2.4 
6.3 ? 2.3 
5.7 + 2.5 
8.0 2 2.3 
Nitroglycerin 
Nadir Peak 
3.5 + 1.7 5.9 r 1.4 
4.1 c 1.7 4.9 2 1.8 
7.8 + 2.0 7.7 * 2.1 
5.2 2 2.0 6.0 + 1.9 
4.2 t 2.2 5.1 2 2.0 
7.9 + 2.4 7.9 ? 2.5 
4.3 + 2.3 6.4 + 2.1 
4.7 r 2.5 5.7 r 2.4 
8.5 f 2.1 8.4 ? 2.2 
Diltiazem 
Nadir Peak 
3.5 r 1.5 5.9 + 1.6 
4.0 2 1.9 4.9 * 1.7 
7.8 2 2.1 7.7 t 2.0 
5.2 + 2.1 6.1 ‘_ 2.1 
4.2 f 2.1 5.2 2 2.0 
7.9 t 2.5 7.9 * 2.5 
4.1 + 2.5 6.4 r 2.2 
4.7 2 2.5 5.6 2 2.5 
8.4 2 2.2 8.4 r 2.2 
Post 
SQ29548 
or LY53857 
6.6 t 1.4 
5.3 * 1.4 
7.6 + 2.1 
6.0 2 2.0 
5.2 + 2.1 
7.8 ? 2.4 
7.0 2 2.0 
6.2 ? 2.4 
8.3 ? 2.2 
Data are expressed as mean values t SEM. CA0 = IO s mechanical coronary artery occlusion; LCx = left circumflex coronary artery. Nadir is defined as 
the lowest flow recorded before flow restoration. See text for details. 
our laboratory (25), in the same animal preparation used in 
the present study, we demonstrated that intracoronary plate- 
let aggregation associated with cyclic flow variations leads to 
a marked focal vasoconstriction of large epicardial coronary 
arteries and that thromboxane A, and serotonin released 
from activated platelets play a major role in mediating this 
vasoconstriction. Intense vasoconstriction occurred only 
immediately distal to the stenosis, where platelet deposition 
has been shown to be maximal (40) and where local concen- 
trations of mediators released from platelets are likely to be 
elevated (4,5). 
The major &dings of the present study are as foiiows: 
First, intravenous administration of nitroglycerin and dilti- 
azem exerted no major effect on platelet aggregation in vivo, 
as demonstrated by the fact that cyclic flow variation fre- 
quency and severity were not affected by either drug. A 
weak antiplatelet effect was observed only during intracor- 
onary infusion of nitroglycerin, as cyclic flow variation 
frequency significantly decreased from a control value of 
7.7 ? 0.4 to 5.6 ? 0.5 cycles/30 min during nitroglycerin 
administration. Second, nitroglycerin and diltiazem given 
intravenously at doses of 5 and 15 pg/kg per min, respec- 
tively, did not reduce the extent of coronary artery vasocon- 
striction associated with cyclic flow variations (Table 3). 
Similarly, no significant reduction of coronary vasoconstric- 
tion was observed when nitroglycerin and diltiazem were 
administered directly into the left anterior descending artery 
at the respective dose of 21 + 5 and 15 pg/kg per min. 
The reasons underlying the lack of eflects of nitroglycerin 
and diltiazem in inhibiting platelet aggregation in vivo and 
reducing the vasoconstriction associated with it are not clear 
and cannot be completely defined from the data obtained in 
the present study. Failure of nitroglycerin and diltiazem to 
decrease vasoconstriction immediately distal to the stenosis 
(LADl) during cyclic flow variations cannot be attributed to 
an inappropriately small dosage of the drugs. Indeed, both 
drugs caused significant decreases in systemic arterial pres- 
sure and significant increases in circumflex artery cross- 
sectional area, thus indicating that the doses employed were 
sufficient to induce dilation of the systemic vascular bed and 
of large epicardial coronary arteries. Moreover, we also 
infused nitroglycerin and diltiazem, in a separate group of 
animals, directly into the left anterior descending artery. 
However, once again, no major reduction in the activated 
platelet-dependent coronary artery vasoconstriction was ob- 
served at the LAD1 site. 
Failure of nitroglycerin to inhibit platelet aggregation in 
vivo in this model is not a totally unexpectedfinding. In fact, 
several studies (41,42) have described lack of inhibitory 
effects of nitroglycerin on platelet function in vitro. Another 
study (14) reported inhibition of platelet function in vitro 
only at suprapharmacologic concentrations of the drug (for 
instance, 800 PM), which are probably never reached in the 
clinical setting. A more surprising finding in our study is that 
neither nitroglycerin nor diltiazem reduced the extent of 
coronary vasoconstriction associated with platelet activa- 
tion. In a recent study, Lam et al. (18) reported that in vivo 
nitroglycerin infusion titrated to decrease mean arterial 
pressure by about 10% can reduce arterial wall platelet 
deposition and the vasoconstriction related to it in porcine 
carotid arteries after experimental angioplasty. Further- 
more, Goldsmith and Turitto (43) described the occurrence 
of spontaneous coronary vasoconstriction in humans after 
coronary angioplasty, which can be prevented by adminis- 
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tration of nitroglycerin. However, the experimental prepa- 
ration used in the present study differs significantly from that 
used by these authors (18,43). First, in the study by Lam et 
al. (18), nitroglycerin was administered at a very high dose, 
1,151 2 235 pg/min, to obtain a decrease in mean arterial 
pressure of about lo%, because pigs are remarkably resis- 
tant to this drug. However, it is possible that this resistance 
involves porcine more than canine smooth muscle, while 
platelets retain a normal sensitivity to nitroglycerin. Second, 
the coronary artery stenosis employed in our model might 
have greatly enhanced platelet reactivity by exposure of 
subendothelium. In fact, it is known that a severe arterial 
narrowing leads to increases in shear rates (44) and that 
under these conditions platelet activation and deposition on 
the arterial wall are enhanced (40). Therefore, it seems 
reasonable to hypothesize that in the model we used, the 
combination of a severe stenosis with endothelial injury 
might represent a stronger aggregating stimulus than that 
used in the previous studies (18,43) (for instance, arterial 
damage without stenosis), which could not be prevented 
even when nitroglycerin and diltiazem were infused directly 
into the left anterior descending artery. If platelet deposition 
was not reduced by nitroglycerin and diltiazem, it is also 
possible that chemical mediators released from activated 
platelets, such as thromboxane A, and serotonin, were 
increased in concentration at the site of maximal platelet 
accumulation (LADl) and that nitroglycerin and diltiazem 
were not adequate to counteract their vasoconstricting ef- 
fects. 
Both SQ29548, a thromboxane A, receptor antagonist, 
and LY53857, a serotonin receptor antagonist, were effec- 
tive in abolishing cyclic flow variations and the coronary 
vasoconstriction associated with them in the same dogs in 
which nitroglycerin and diltiazem exerted no effect, thus 
providing further evidence that thromboxane A, and seroto- 
nin are mediators of activated platelet-related coronary 
vasoconstriction in this experimental model. 
Conclusions. It is currently believed that intracoronary 
platelet activation plays a major role in the pathophysiology 
of unstable angina. In particular, angiographic and angio- 
scopic evidence suggest that plaque ulceration and in situ 
coronary thrombosis are frequent findings in patients with 
unstable angina (l-3). In addition, metabolic studies (4-8) 
have suggested that periodic platelet activation occurs in 
patients with unstable angina, and that this may eventually 
lead to coronary occlusion either by formation of a thrombus 
or by release of platelet-derived substances, or both, which 
may, in turn, cause coronary vasoconstriction. In so far as 
data obtained in experimental preparations can be extrapo- 
lated to humans, the present study supports the hypothesis 
that thromboxane A, and serotonin may be mediators of 
activated platelet-induced coronary vasoconstriction. Nitro- 
glycerin and diltiazem are relatively ineffective in reducing 
this coronary vasoconstriction, whereas thromboxane A? or 
GOLINO ET AL. 725 
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serotonin receptor antagonists prevented platelet-mediated 
vasoconstriction in this experimental model. 
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